Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Replagal in Indian Children and Adults With Fabry Disease
NCT05067868Phase 4Recruiting
- Sponsor
- Takeda
- Start
- Nov 2022
- Primary completion
- Oct 2027
- Modality
- Replacement Enzymes
- Countries
- 1
01
Overview
A Phase 4 trial of agalsidase alfa in Fabry disease (FD), sponsored by Takeda. Started Nov 2022; status: recruiting.
02
Drugs
agalsidase alfa
03
Conditions
Fabry disease (FD)
Beyond the preview
Go deeper on NCT05067868.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05067868.